|
⚲
|
| Keyboard |
| William Rieflin | |
|---|---|
| Firm | |
| Address | c/o Rapt Therapeutics, Inc 561 Eccles Ave South San Francisco, CA 94080 |
| Source |
| Associated Funds | Form D | Role | 2011 - 2026 | Raised | AUM |
|---|---|---|---|---|---|
| Lycia Therapeutics Inc | 021-588627 | Director | 75.0 M of 75.0 M |
||
| RAPT Therapeutics Inc | 021-534152 | Director | 150.0 M of 150.0 M |
||
| NGM Bio Holdings Inc | 021-519045 | Director | 142.0 M of 142.0 M |
||
| Lycia Therapeutics Inc | 021-514102 | Director | 106.6 M of 106.6 M |
||
| RAPT Therapeutics Inc | 021-448024 | Director | 50.0 M of 50.0 M |
||
| Lycia Therapeutics Inc | 021-413559 | Director | 70.1 M of 70.1 M |
||
| RAPT Therapeutics Inc | 021-329374 | Director | 37.1 M of 67.1 M |
||
| FLX Bio Inc | 021-302312 | Director | 29.9 M of 59.9 M |
||
| FLX Bio Inc | 021-262612 | Director | 50.0 M of 50.0 M |
||
| Kallyope Inc | 021-249469 | Director | 28.1 M of 44.0 M |
||
| NGM Biopharmaceuticals Inc | 021-236650 | Executive Officer | 106.0 M of 106.0 M |
||
| Flexus Biosciences Inc | 021-236314 | Director | 15.2 M of 15.2 M |
||
| NGM Biopharmaceuticals Inc | 021-234589 | Executive Officer | 20.7 M of 60.0 M |
||
| Anacor Pharmaceuticals Inc | 021-198076 | Director | of 2.7 M |
||
| NGM Biopharmaceuticals Inc | 021-195932 | Executive Officer | 13.5 M of 50.0 M |
||
| Anacor Pharmaceuticals Inc | 021-194691 | Director | 5.0 M of 5.0 M |
||
| Xenoport Inc | 021-187248 | Director | 20.0 M of 40.0 M |
||
| NGM Biopharmaceuticals Inc | 021-114428 | Executive Officer | 55.4 M of 55.7 M |
||